IF any of xoma's clients come up with a drug, there is going to be a rush to buy out xoma. they could save all the royalty payments and collect royalty payments from others by doing so.
This stock still has dangerous upside.
They are in the hottest biotech field right now, antibodies for cancer and other diseases, including infections.
antibiotics are hard to come by and have narrow usage.
true, stock looks expensive, but they only have 8 million O/S!
Market Data 
Markets 
AI
